ANO1 (TMEM16A) overexpression is frequently observed in cancer tissues and is closely correlated with poor prognosis, making it a potential biomarker and target for cancer treatment.
Since anoctamin 1 ANO1 (TMEM16A) was found to be a molecular component of Ca(2+) -activated Cl(-) channels, its role in tumorigenesis has gained attention at a fast pace. ANO1 overexpression frequently occurs in the cancer tissues along with 11q13 chromosome amplification. Poor prognosis of many types of cancers has been closely correlated with ANO1 gene amplification and protein overexpression. ANO1 is now considered an excellent biomarker for certain cancers. Recent research suggests that it is the channel function of ANO1 that is involved in the tumorigenesis. However, how the overexpression of the functional ANO1 causes malignant transformation of tissues via signaling pathways, for example, MAPK remains to be investigated. Clarification of the reasons in future will avail to make ANO1 as a target for cancer treatment.
Qu et al. (2014) conducted a review in Cancer. ANO1 (TMEM16A) overexpression was evaluated on Tumorigenesis and poor prognosis. ANO1 (TMEM16A) overexpression is frequently observed in cancer tissues and is closely correlated with poor prognosis, making it a potential biomarker and target for cancer treatment.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: